TARGET POPULATION ESTIMATES USING REAL WORLD EVIDENCE (RWE) IN RARE DISEASES: A CASE STUDY IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN)

被引：0
|
作者：
Kwon, C. [1 ]
Daniele, P. [2 ]
Forsythe, A. [3 ]
Ngai, C. [4 ]
机构：
[1] Purple Squirrel Econ, Southborough, MA USA
[2] Purple Squirrel Econ, Montreal, PQ, Canada
[3] Purple Squirrel Econ, New York, NY USA
[4] Calliditas Therapeut, Long Isl City, NY USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK12
引用
收藏
页码：S236 / S236
页数：1
相关论文
共 26 条
  • [1] IS THERE A NEED FOR REAL WORLD EVIDENCE (RWE) IN HEALTH TECHNOLOGY ASSESSMENTS OF RARE DISEASES AND ONCOLOGY TREATMENTS?
    Forsythe, A.
    Tomaras, D.
    Badia, F. J.
    Pirk, O.
    Rowe, P.
    Bergman, J. F.
    Walker, A.
    Fricke, F. U.
    Tremblay, G.
    [J]. VALUE IN HEALTH, 2019, 22 : S811 - S811
  • [2] A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases
    Vaghela, Shailja
    Tanni, Kaniz Afroz
    Banerjee, Geetanjoli
    Sikirica, Vanja
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [3] A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE (RWE) SUPPORTIVE OF NEW DRUG AND BIOLOGIC LICENSE APPLICATION APPROVALS IN RARE DISEASES
    Tanni, K. A.
    Vaghela, S.
    Banerjee, G.
    Sikirica, V
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S230 - S231
  • [4] A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases
    Shailja Vaghela
    Kaniz Afroz Tanni
    Geetanjoli Banerjee
    Vanja Sikirica
    [J]. Orphanet Journal of Rare Diseases, 19
  • [5] Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label
    Zong, Jihong
    Jiao, Xiaolong
    Pan, Lucy
    Castelo, Sarah
    Campbell, Chelsey
    Lennert, Barb
    Bruno, Amanda
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] COMPARISON OF THE USE OF REAL-WORLD EVIDENCE (RWE) BY HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES IN REVIEWS OF DRUGS FOR RARE DISEASES (DRDS)
    Kirby, J.
    Tadros, N.
    Gosain, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S508 - S508
  • [7] Seasonality of allergic diseases: Real-world evidence from a nationwide population-based study
    Lee, Young Chan
    Ju, Hyun Jeong
    Kwon, Jin-woo
    Bae, Jung Min
    [J]. IMMUNITY INFLAMMATION AND DISEASE, 2020, 8 (03) : 360 - 362
  • [8] Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example
    Gross, Andrea M.
    [J]. CURRENT PROBLEMS IN CANCER, 2021, 45 (04)
  • [9] CAN AN INTEGRATED SYSTEMATIC LITERATURE REVIEW (SLR) DATABASE IMPROVE THE SPEED OF TITLE AND ABSTRACT (TIAB) REVIEW? A CASE STUDY USING MULTIPLE MYELOMA (MM) PROJECTS IN INTERVENTIONAL AND REAL-WORLD EVIDENCE (RWE) EVIDENCE
    Liu, R.
    Mosselman, J. J.
    Hanegraaf, P.
    van der Schans, J.
    Rizzo, M.
    Forsythe, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
  • [10] COMPARATIVE EFFECTIVENESS ANALYSIS USING REAL WORLD EVIDENCE (RWE) AND APPLYING A CAUSAL MARGINAL STRUCTURAL MODEL: THE CASE OF SECOND-LINE TREATMENT IN PATIENTS WITH OVARIAN CANCER
    Siebert, U.
    Kuehne, F.
    Arvandi, M.
    Hess, L. M.
    Faries, D. E.
    Beyrer, J.
    Gothe, Matteucci H.
    Gothe, H.
    Stojkov, I
    Rochau, U.
    Oberaigner, W.
    Zeimet, A. G.
    Marth, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S18 - S18
123